摘要:
The present invention discloses novel compounds useful as alkaline phosphatase inhibitors and therapeutic agents. Preferably, the novel compounds are useful as selective inhibitors of human alkaline phosphatases as opposed to Escherichia coli alkaline phosphatases. The novel compounds can also be used as cancer therapeutic agents, anti-depressive agents, anti-anergic agents, and antihelminthic agents. The novel compounds have the following general formula: ##STR1## wherein R' is an aryl, aryl ether, aryl thioether, aromatic heterocyclic, aromatic heterocyclic thioether, or aromatic heterocyclic ether group. More preferably, R' is a phenyl or a pyridine. Most preferably, R' is of the following formula: ##STR2## 2-thiopyridine, or ##STR3## 2-oxypyridine. R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.1 ', R.sub.2 ', R.sub.3 ', R.sub.4 ', and R.sub.5 ' can be the same or different, and at least one of which is selected from the group consisting of: H, C.sub.1 -C.sub.6 alkyl, halo C.sub.1 -C.sub.6 alkyl, phenyl, C.sub.1 -C.sub.6 alkoxy, phenoxy, trifluoromethyl, nitro, amino, carboxy, and halo groups with the proviso that each novel compound has no more than three substituents. Hydrogen is not considered a substituent.
摘要:
Described are compounds of the formula ##STR1## wherein R is hydrogen or loweralkyl, X, Y and W independently of one another denote hydrogen, halogen, loweralkyl, nitro, amino, amido, loweralkoxy, hydroxy, nitrile, methylsulfone, methylsulfoxide, methylmercapto, or trifluoromethyl; Z is oxygen, sulfur or --CH.sub.2 ; n and m are each an integer from 0 to 6 inclusive, or pharmaceutically acceptable salts thereof.The compounds are effective as anti-inflammatory agents.
摘要:
Compounds of formula (SEQ ID NO:2) and (SEQ ID NO:3), which are useful for treating conditions that arise from or are exacerbated by angiogenesis, are described. Also disclosed are pharmaceutical compositions comprising these compounds, methods of treatment using these compounds, and methods of inhibiting angiogenesis.
摘要翻译:描述了可用于治疗由血管生成引起或加重的病症的式(SEQ ID NO:2)和(SEQ ID NO:3)的化合物。 还公开了包含这些化合物的药物组合物,使用这些化合物的治疗方法,以及抑制血管发生的方法。
摘要:
Compounds of formula (SEQ ID NO:1), which are useful for treating conditions that arise from or are exacerbated by angiogenesis, are described. Also disclosed are pharmaceutical compositions comprising these compounds, methods of treatment using these compounds, and methods of inhibiting angiogenesis.
摘要翻译:描述了可用于治疗由血管生成引起或加剧的病症的式(SEQ ID NO:1)的化合物。 还公开了包含这些化合物的药物组合物,使用这些化合物的治疗方法,以及抑制血管发生的方法。
摘要:
Peptides having the formula: A0-A1-A2-A3-A4-A5-A6-A7-A8-A9-A10 wherein A0 is selected from hydrogen or an acyl group; A10 is a hydroxyl group or an amino acid amide; and A1, A2, A3, A4, A5, A6, A7, A8, and A9 are amino acyl residues as defined herein.
摘要翻译:具有以下结构式的肽:<?in-line-formula description =“In-line Formulas”end =“lead”?> A 1 sub> > 2 sub> 3→3→3→3→5→ - →3→ > 7 u> -A i> i> i> i> u> “end =”tail“?>其中A 选自氢或酰基; A 10是羟基或氨基酸酰胺; 和A 1,A 2,A 3,A 4,A 5, A 6,A 7,A 8和A 9是如本文所定义的氨基酰基残基。
摘要:
Tetrahydroisoquinoline derivatives of the formula: ##STR1## or a pharmaceutically acceptable salt, ester, or prodrug thereof, having activity as an LHRH antagonist, as well as pharmaceutical compositions containing the same, and methods for their use and preparation.
摘要:
The present invention relates to novel "pseudo" nonapeptide and decapeptide derivatives of LHRH. More particularly the present invention relates to derivatives of LHRH wherein the nitrogen atom of at least one of the amide bonds has been alkylated.
摘要:
Described are oxazolyl (or thiazolyl) hydrazinoalkyl nitrile compounds of the formula ##STR1## wherein R is hydrogen or loweralkyl, R.sub.1 and R.sub.2 independently of one another denote hydrogen, loweralkyl, or phenyl or naphthyl substituted with halo, loweralkyl or loweralkoxy, X is oxygen or sulfur, n and m are each an integer from 0 to 3 inclusive, or pharmaceutically acceptable salts thereof. The compounds are useful as anti-inflammatory agents.
摘要:
It has been found that certain 4-substituted 2-hydroxylaminomethyl phenols or their nontoxic pharmaceutically acceptable acid addition salts are excellent diuretic, saluretic and anti-inflammatory agents.